Objectives: To ascertain the effects of subinhibitory concentrations of several antifungal agents on a virulence factor: secreted proteinase (Sap) activity and expression of SAP genes in Candida albicans.
Introduction
Like many antimicrobial agents, antifungal agents have been shown to exert pharmacological effects beyond inhibition of fungal growth. Among many examples, fluconazole has been shown to inhibit adhesion of Candida species to acrylics 1 and buccal epithelial cells. 2 Amphotericin B and several azole antifungals have been shown to augment phagocytic effects of polymorphonuclear leucocytes [3] [4] [5] and macrophages, 6, 7 and amphotericin B induces chemokine expression 8 and alters non-specific proliferative responses 9 of monocytes. Some studies have suggested an effect of antifungal agents on expression of virulence factors by Candida albicans. Willis et al. 10 treated diabetic patients with nystatin or fluconazole and found that fluconazole treatment, but not nystatin treatment, appeared to reduce phospholipase production by C. albicans isolates colonizing and infecting the mouth. Lass-Florl et al.
11
demonstrated that sertraline, a serotonin reuptake inhibitor, activated monocyte-directed macrophages against Candida species and reduced levels of fungal phospholipase and proteinase activities. Wu et al. 12 showed that exposure of a fluconazole-susceptible C. albicans isolate to fluconazole at sub-MIC concentrations led to a reduction in the specific activity of secreted aspartyl proteinases (Saps), whereas the same treatment of a fluconazole-resistant isolate led to an increase in extracellular proteinase specific activity. Saps are the products of a family of 10 SAP genes; Sap2 is the enzyme expressed predominantly under proteinase-inducing conditions in vitro. 13 Ripeau et al. 14 showed induction of SAP5 expression in cells treated with caspofungin.
As part of a wider ranging survey of possible links between antifungal exposure and expression of virulence factor genes in C. albicans, we have studied in detail the effects of antifungal agents representing four major classes of such agents on the expression of SAP genes and Sap activity, using a range of molecular biological approaches. We show that exposure to azoles, flucytosine and caspofungin all gave an increase in SAP2 expression and in Sap specific activity under proteinase-inducing conditions.
Materials and methods

Fungal isolates
All wild-type C. albicans isolates tested were originally obtained from clinical sources. SC5314 and 88/025 were blood isolates; both are susceptible to amphotericin B, flucytosine, caspofungin and azoles. SC5314 is also the parent strain widely used for specific gene disruption studies in C. albicans and it was the progenitor of caspofungin-resistant mutant NR3. 15 J990578 and TW12-99 were oral isolates from patients with AIDS; both are resistant to azole antifungal agents; J990578 is additionally resistant to flucytosine. All isolates were maintained either on Sabouraud agar (Oxoid) or by longer-term storage at À808C in 25% glycerol.
Strains derived from SC5314 and specifically disrupted in SAP genes 1 to 6 16, 17 were transformed with plasmid CIp10 18 to ensure adequate expression of URA3 at the RPS1 locus. 19 This procedure created VC1 (ura3D::imm434/ura3D::imm434/sap1D::hisG/sap1D:: hisG/RPS1::CIp10-URA3), VC2 (ura3D::imm434/ura3D::imm434/ sap2D::hisG/sap2D::hisG/RPS1::CIp10-URA3), VC3 (ura3D::imm434/ ura3D::imm434/sap3D::hisG/sap3D::hisG/RPS1::CIp10-URA3) and VC4-6 (ura3D::imm434/ura3D::imm434/sap6D::hisG/sap6D::hisG sap4D::hisG/sap4D::hisG sap5D::hisG/sap5D::hisG/RPS1::CIp10-URA3). Strains Dsap9 and Dsap10 were disrupted in SAP9 and SAP10, respectively and had URA3 reintegrated at the RPS1 locus. 20 Detailed descriptions of these mutants will appear in a separate publication.
Construction of SAP2 promoter GFP fusion
To make the plasmid, pSAP2-GFP, the CaSAP2 promoter region (À9 to À979) was PCR-amplified using the primers 5 0 -ACCTCGAGATCAAATGTGTTACC and 5 0 -TGAAGCTTGGTGA-TGTTTAGTGG (XhoI and HindIII sites underlined) and cloned between the XhoI and HindIII sites of pGFP. 21 The plasmid was linearized by digestion with BglII and used to transform C. albicans strain CAI-4. Single copy integrants were screened by PCR as previously described 20 and confirmed by Southern analysis.
Fluorescence measurements
An Axioplan 2 microscope (Carl Zeiss Ltd, UK) with filter sets XF 66, XF 67 and XF 77 (Omega Optical Inc., Brattleboro, VT, USA) was used for fluorescence microscopy. Images were generated with a Hamamatsu CCD camera, and analysed with Openlab 3.0.9 software (Improvision Ltd, Coventry, UK). Mean fluorescence intensities ( ± SD) were then calculated for at least 50 individual cells based on region of interest measurements. 21 
Antifungal agents
Flucytosine was purchased from Sigma. Amphotericin B was purchased as Fungizone. Other agents were gifts from Merck, Inc. (itraconazole and miconazole) . Caspofungin, fluconazole and flucytosine stock solutions were prepared in sterile distilled water. Itraconazole and miconazole were dissolved in DMSO. In all experiments, drug dilutions were prepared at 100 times final concentration in the appropriate solvent and added to 100 volumes of culture medium.
Growth under proteinase-inducing conditions
Conditions for induction of cultures expressing Sap activity were essentially the same as used by Wu et al. 12 Briefly, yeast carbon base/bovine serum albumin (YCB/BSA) medium containing 1.17% YCB (BD Biosciences), 1% glucose and 0.5% BSA (Sigma) was inoculated to 1-3Â10 5 cells/mL from an overnight culture of C. albicans and incubated at 308C on a rotary shaker or rotating wheel. Additions of antifungal agents or their solvents were made after 6 h of growth. Growth in the presence and absence of antifungal agents was measured as OD 600 versus a YCB/BSA blank. Growth in the presence of antifungal agents was expressed as a percentage of control (drug-free) growth. For each isolate tested, preliminary susceptibility tests in YCB/BSA were used to determine subinhibitory concentrations of antifungal agents. MICs determined under these conditions were within one dilution of MICs determined by standard (CLSI) methodology. Because the dose -response curves for all agents tested except amphotericin B contained regions of partial growth inhibition, the results of experiments relating proteinase activity to antifungal treatments were expressed as scatterplots of relative growth (% of control) versus relative Sap specific activity (% of control). This approach reduced the impact of interrun variability in the data. Data were excluded when growth was inhibited below 25% of control; proteinase activities in filtrates of such strongly inhibited cultures were irreproducibly low.
Proteinase assay
Proteinase-inducing cultures were set up in 5 mL volumes as described above. After 72 h of incubation, growth was measured by spectrophotometry at 600 nm. One millilitre volumes of cultures were centrifuged at 13 000 g for 1 min and the supernatant retained. The assay mixture comprised 0.5 mL of 1% BSA in 0.1 M citrate buffer pH 3.0 as substrate and 0.25 mL of culture supernatant. The mixture was incubated for 1 h in a 378C water bath. The reaction was stopped with 1.25 mL of ice-cold 5% trichloroacetic acid (TCA). Precipitated material was removed by centrifugation and the OD 280 of the supernatant was determined against a blank prepared by addition of TCA at the start of the incubation period.
RT -PCR
For measurement of the expression of SAP2, SAP9 and EFB1 by RT-PCR, cells were grown in proteinase-inducing medium in the presence or absence of antifungal agents for 72 h. EFB1 contains an intron and was included as a control for genomic DNA contamination of cDNA. The concentrations of antifungal agents used were chosen to inhibit growth of the C. albicans strains tested to 50-80% of control values. RNA was extracted 22 and treated with DNase I (Invitrogen) to remove DNA. Each sample included 6 mg of RNA, 2 mL of DNase I buffer (Invitrogen), 1.5 mL of DNase I and 1.5 mL of RNase OUT (Invitrogen) made up to 20 mL with RNase-free water. The samples were incubated at room temperature for 15 min followed by the addition of 2 mL of 25 mM RNase-free EDTA (Invitrogen) and incubated at 658C for 15 min.
cDNA was generated by addition of 2 mL of Oligo (dT)12 -18 primer (500 mg/mL) (Promega) to the DNase I-treated RNA, incubated at 708C for 10 min and snap-cooled on ice for 2 min to denature. First-strand cDNA was synthesized by addition of 8 mL of 5Â First Strand Buffer, 4 mL of 0.1 M dithiothreitol (DTT), 2 mL of 2.5 mM dNTP mixture (Invitrogen) and 2 mL of RNase OUT. The mixture was incubated at 428C for 2 min followed by the addition of 2 mL of Superscript II reverse transcriptase (200 U/mL) (Invitrogen) and reincubation for 60 min at 428C. The reaction was stopped by incubation at 708C for 15 min.
Single and multiplex PCRs were done with 2Â PCR Master Mix (ABgene). In single PCRs, 25 mL of 2Â PCR master mix, 22 mL of water, 1 mL of SAP2-5 primer (CCTAAAGCATTCCCAGGTTAC) or SAP9-5 primer (GGTGCATATTCAACGTTCTCC), 1 mL of reverse primer SAP2-3 (CTTAGGTCAAGGCAGAAATACTG) or SAP9-3 (CTATGTCGACTGTTCTGCTG) and 1 mL of cDNA were added. In multiplex reactions of EFB1/SAP2 or EFB1/SAP9, 25 mL of 2Â PCR master mix, 21 mL of water, 1 mL of EFB1-5 (ATTGA-ACGAATTCTTGGCTGAC), 1 mL of EFB1-3 (CATCTTCTTCAA-CAGCAGCTTG), 1 mL of SAP2-5 or SAP9-5, 1 mL of SAP2-3 or SAP9-3 and 1 mL of cDNA were added. SAP2 PCRs were carried out with an initial denaturing step of 948C for 5 min, followed by 30 cycles of 1 min denaturation at 948C, annealing for 1 min at 508C and extension for 1 min at 728C, with a final extension of 10 min at 728C. SAP9 PCR had an annealing temperature of 558C for 1 min.
To determine gene expression in a semi-quantitative manner, we sampled every second PCR from cycle 16 to cycle 30 and estimated amounts of gene products relative to EFB1.
Transcript profiling with C. albicans microarrays
To measure expression of most C. albicans genes in cells of SC5314 grown for 72 h in proteinase-inducing conditions with and without addition of fluconazole at 2 mg/L, the cells were flash-frozen in liquid nitrogen and the RNA extracted as described above. The 72 h incubation time ensured maximum growth and proteinase induction in the medium.
From the extracted RNA, a pooled control was prepared containing equal concentrations of RNA from the cells not treated with fluconazole. cDNA was prepared from the RNA samples by reverse transcription. In brief, 2 mg of oligo (dT)12-18 primer (500 mg/mL) (Promega) was added to 50 mg of RNA and made up to 10 mL with RNase-free H 2 O, incubated for 10 min at 708C and snap-cooled on ice for 1 min. Individual lots of the pooled control sample were then labelled with the dye Cy3-dUTP by reverse transcription. To each control RNA sample, 15 mL of labelling master mix (1Â RT buffer, 1 mM DTT, 500 mM dATP, 500 mM dCTP, 500 mM dGTP, 100 mM dTTP) was added followed by 3 mL of Cy3-dUTP (Amersham Biosciences). The triplicate experimental (control and fluconazole-treated) samples were individually labelled with Cy5-dUTP (Amersham Biosciences) by the same method. Following the addition of the label, 2 mL of Superscript II reverse transcriptase (Invitrogen) was added, mixed thoroughly and incubated at 428C for 2 h. The reaction was stopped by the addition of 1.5 mL of 20 mM EDTA, followed by 1.5 mL of 500 mM NaOH and incubated for 10 min at 708C to degrade the RNA. This reaction was neutralized by the addition of 1.5 mL of 500 mM HCl. Following reverse transcription, the samples were mixed (pooled control 1: fluconazoletreated 1; pooled control 2: fluconazole-treated 2; pooled control 3: fluconazole-treated 3) and purified in a GFX purification column (Amersham Biosciences) following the manufacturer's procedure, then concentrated in the Speed Vac to 20 mL.
Three independent hybridizations were carried out for each experimental condition against the pooled control (pooled control 1: fluconazole-treated 1; pooled control 2: fluconazole-treated 2; pooled control 3: fluconazole-treated 3). To control for intrinsic biological (experimental) variation, pooled controls labelled with Cy3 were also tested against individual Cy5-labelled control samples.
Eurogentec C. albicans microarray slides, representing 95% of the genome, were pre-hybridized in 5Â SSC/1% SDS/1% BSA for 45 min at 428C, washed five times in water, once in isopropanol and air-dried. The labelled samples were added to 20 mL of hybridization solution (50% formamide/10Â SSC/0.2% SDS), boiled to denature for 3 min and carefully added to the printed part of the microarray slide and the lifter slip placed on the slide. The slides were incubated at 428C overnight. Slides were washed at room temperature in 2Â SSC/1% SDS for 15 min, 1Â SSC/0.2% SDS for 8 min and 0.1Â SSC/0.2% SDS for 5 min. The slides were centrifuged to dry, then read in the scanner. The slides were scanned at different wavelengths so that when the dual images were opened together, each spot lit up either as a yellow colour or in varying shades of green or red, depending on the relative level of expression of the individual gene in each spot.
Signals on the slides were located with a ScanArray 4000 Microarray Analysis System, and quantified with QuantArray Acquisition Software. The raw data were normalized according to the Lowess algorithm, then analysed with the program GeneSpring. GeneSpring data were further analysed statistically with Statistical Analysis of Microarray (SAM) software to identify genes that displayed statistically significant changes in their expression, and to minimize the number of false positives in the lists of genes that were up-or down-regulated. The cut-off point in this experiment was 2-fold regulation. The CandidaDB gene annotation was used to assign gene functions, and the $6000 genes were assigned to functional categories on the basis of the MIPS functional categorization of S. cerevisiae genes (http://mips.gsf.de/genre/proj/yeast/ index.jsp).
Results
Effects of antifungal agents on Sap enzyme activity C. albicans isolates SC5314, J990578 and NR3 were tested extensively for Sap activity in the presence and absence of sub-MIC concentrations of several antifungal agents. For the azole-susceptible isolates SC5314 ( Figure 1a ) and NR3 (Figure 1b) , Sap specific activity increased progressively with inhibition of growth by azole antifungals, reaching 150-200% of control values when growth was reduced by 50%. The opposite effect was seen with azole-resistant J990578 (Figure 1c) , where Sap activity decreased to 50% of control values when growth was inhibited by 50%. Tests with two further C. albicans isolates, including one that was resistant to azoles, showed Sap specific activities increasing as growth was inhibited, in the same way as SC5314 and NR3. To date, J990578 is the sole isolate among eight we have tested with fluconazole that showed a decrease in Sap specific activity as growth was inhibited. The other seven isolates all showed an inverse relationship between Sap specific activity and growth.
Exposure of SC5314 and NR3 to flucytosine generated a similar increase in Sap specific activity proportional to the decrease in growth relative to control (Figure 2c ). For J990578, we were unable to obtain flucytosine concentrations high enough to inhibit growth of this highly resistant strain, hence no relationship between growth and Sap activity could be determined (Figure 2c) . Effects of amphotericin B on Sap activities in SC5314, NR3 and J990578 were difficult to determine, since partial growth inhibition by amphotericin B was rarely seen. When growth inhibition exceeded 75%, the levels of Sap enzyme activity tended to fall below the threshold of detection, probably because the fungi were killed by this cidal agent.
Where occasional partial growth inhibition with measurable growth activity did occur, exposure of SC5314 and NR3 to amphotericin B seemed to generate a rise in Sap specific activity whereas exposure of J990578 gave a fall in Sap activity ( Figure  2a) . These effects were similar to those seen on exposure to flucytosine and azole antifungals. However, the number of data points corroborating the relationship was small for amphotericin B.
For caspofungin (Figure 2b ), the effects of the drug on Sap specific activity produced by SC5314, NR3 and J990578 were less reproducible than with the other agents tested. For drug concentrations where growth was below 50% of control, the Sap activities followed no obviously definable pattern. Above 50% of control growth, a weak inverse relation between Sap activity and growth was seen for all three strains.
As with the azole antifungals, two other C. albicans isolates, 88/025 and TW12-99, showed responses similar to SC5314 and NR3 when treated with antifungal concentrations that partially inhibited growth (details not shown). Figure 3 shows the results of experiments in which C. albicans cells containing a pSAP2-GFP construct were grown in YCB/BSA medium with and without additions of fluconazole. After 48 h and 72 h of incubation, the mean fluorescence values for cells exposed to fluconazole at 1 mg/L were significantly higher than those of cells grown in the absence of fluconazole (Student's t-test, P < 0.0001). At 0.5 mg/L (Figure 3 ) and lower fluconazole concentrations (not shown), mean fluorescence was of the same order as in control cells at all three times. This indicates that the GFP-tagged SAP2 promoter was expressed at higher levels in Sap-induced cells exposed to 1 mg/L fluconazole, a finding consistent with the increased specific enzyme activity measured in filtrates from wild-type SC5314 grown under the same conditions (Figure 1) . However, the sensitivity of the cell fluorescence assay was lower than that of the enzyme assay, since the latter revealed the fluconazole effect at lower concentrations than the GFP test. The enzyme assay also detects the activity of the secreted Sap2 gene product, while the fluorescence assay detects promoter activity within the cells.
Pepstatin A is a specific inhibitor of Sap activity, but does not affect other proteinases. To double-check that the increase in secreted proteinase in response to fluconazole was not the result of up-regulation of non-Sap proteinases, 2 mM pepstatin A was added at the start of a growth experiment in YCB/BSA, with and without addition of fluconazole at 2 mg/L. In the presence of fluconazole and the absence of pepstatin, growth was reduced to 73% of control, and Sap specific activity rose to 134% of control. In cultures where pepstatin was added, with or without fluconazole, no growth occurred by 72 h and no proteinase activity was detectable.
Previous studies have shown that the principal Sap expressed in YCB/BSA medium in vitro is the product of the SAP2 gene. 15 We attempted to test whether C. albicans VC2 (sap2/sap2) displays a fluconazole effect by growing this strain in YCB/BSA. However, no growth was apparent in the absence of fluconazole even after 4 days of incubation, further confirming that any effects measured were attributable to levels of Sap2 secreted. For mutants VC1, VC3, Dsap9 and Dsap10, respectively bearing disruptions of both alleles of SAP1, SAP3, SAP9 and SAP10, the effect of fluconazole on Sap specific activity was indistinguishable from that seen with wild-type SC5314 cells (Figure 4) . Mutant VC4-6, disrupted in SAP4, SAP5 and SAP6, did not grow in the YCB/BSA medium by 96 h of incubation, although growth occurred after a further 2 days of incubation. These results confirm that the elevation of specific Sap activity seen in the presence of inhibitory concentrations of fluconazole and, presumably, in the presence of the other antifungal agents that induce high Sap activities, probably results from a change in SAP2 gene expression.
Expression profiling to investigate the effect of fluconazole under Sap-inducing conditions
We used C. albicans genomic microarrays to compare levels of expression of nearly all C. albicans genes in cells of SC5314 grown for 72 h in proteinase-inducing conditions with and without addition of fluconazole at 2 mg/L (growth was inhibited to 40% of control). Statistical analysis of the transcript profiling experiment revealed 88 genes that were significantly up-regulated more than 2-fold in fluconazole-treated cells and 26 that were down-regulated by the same factor (Table 1) . Among the 88 up-regulated genes were 19 related to sugar uptake and metabolism, eight genes encoding enzymes in the ergosterol biosynthesis pathway, eight genes encoding proteins likely to be located and functioning in the cell wall, and therefore candidate factors that interact directly with the host during infection, and two SAP genes, SAP2 and SAP9. Among the significantly downregulated genes were four encoding enzymes in the glyoxylate cycle, which has been shown to play a possible role in the interaction between C. albicans and host phagocytic processes. 23 
RT -PCR to detect gene expression changes in response to antifungal exposure
We used semi-quantitative RT-PCR, with gels run to detect products every two cycles, to confirm the changes in SAP gene expression of C. albicans cells exposed to antifungal agents while growing under Sap-inducing conditions. We compared levels of SAP2 and SAP9 RNA in cells of SC5314 and J990578 exposed to concentrations of fluconazole and caspofungin that reduced growth to around 40-70% of control values by 72 h. Figure 5 shows an overview of results after 30 PCR cycles. Figure 5(a) shows that in SC5314, SAP2 expression was substantially up-regulated in the presence of fluconazole. SAP9 expression, though appearing similar in fluconazole-treated and -untreated cells in Figure 5(a) , was also seen to be up-regulated in semi-quantitative RT-PCR (details not shown). In J990578, Table 1 . List of C. albicans genes that are up-regulated and down-regulated by a factor of more than 2-fold (genes are listed in decreasing order of fold change in expression) 
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SAP2 expression was lower in cells exposed to fluconazole whereas SAP9 expression was substantially higher. For cells exposed to caspofungin (Figure 5b ), an increase in SAP2 expression in SC5314 and a decrease in J990578 were seen similar to that in cells exposed to fluconazole, but expression of SAP9 was lower in caspofungin-treated and -untreated cells.
Discussion
Our study has shown a clear link between expression of a known virulence factor in C. albicans, Sap2, and exposure of the cells to antifungal agents. Four of five C. albicans isolates grown under Sap-inducing conditions responded in a dosedependent manner to partial growth inhibition by caspofungin, flucytosine and three azole antifungal agents by increasing their extracellular Sap enzyme activity. The fifth isolate responded in the opposite manner, with a decrease in Sap activity. These results partly contradict those of Wu et al., 12 who found a decrease in extracellular Sap activity in susceptible strains of C. albicans exposed to fluconazole and an increase in resistant strains. Our isolate that showed a decrease in Sap activity when exposed to fluconazole and other agents was resistant to azoles and flucytosine. Of the four isolates that showed an increase in Sap activity, two were azole-susceptible and two were azole-resistant. We are therefore unable to confirm any general relationship between azole susceptibility and azole-related expression of Sap activity.
We studied the effects on Sap activity of a wider range of antifungal agents than have been previously investigated. Our findings indicate that enhanced Sap activity is induced not by any single class of antifungal agents, but by azoles (which target Erg11p), flucytosine (which inhibits DNA and RNA synthesis), and caspofungin (which targets b-1:3 glucan synthesis). 24 This finding suggests that at least three different classes of growth inhibitor affect a regulator of SAP gene expression.
Among the family of 10 SAP genes that encode aspartyl proteinases in C. albicans, most work to date has been done with SAP1 to SAP6. 25, 26 Little is known about SAP7 to SAP10, but it appears likely that the products of SAP9 and SAP10 are not secreted into the culture medium. 19 The finding that SAP9 mRNA was up-regulated in SC5314 exposed to fluconazole (Table 1) was not expected. However, our data show that the measured increase in extracellular proteinase produced by SC5314 exposed to fluconazole was the result of increased SAP2 expression and was unrelated to expression of SAP9. Since Sap9 is localized on the cell surface, 19 the up-regulation of expression was unlikely to have been reflected in an increase in activity of proteinase secreted externally. The quantitative effect of fluconazole on Sap activity was the same for mutants disrupted in SAP1, SAP3, SAP9 and SAP10, whereas SAP2 and SAP4-6 mutants did not grow in the inducing medium. The probability that genes in the SAP4-6 series were responsible for the increase in Sap activity in fluconazole-treated cells is low; these genes are normally expressed only at neutral pH in media that favour hypha formation by C. albicans;
13,27 their failure to grow in YCB/BSA at the same rate as wild-type cells has been noted previously. 16 The results from the gene expression arrays (Table 1 ) and the RT -PCR experiments point only to SAP2 as the proteinase-encoding gene uniquely regulated by exposure to fluconazole and caspofungin. It would seem surprising if SAP2 were not the gene affected by exposure to other azoles and to flucytosine as well. However, others showed up-regulation of SAP5 expression when C. albicans was exposed to caspofungin in non-inducing conditions, 14 so it is likely that different microenvironments influence the impact of antifungal agents on SAP expression.
De Backer et al. 28 previously reported results of expression profiling for the URA3 À strain CAI-4 grown in the presence of itraconazole at 200 times its MIC and in non-proteinase-inducing conditions. Although the extreme differences in test conditions make comparison of the published data with our own partiallygrowth-inhibitory results difficult, it is notable that seven genes in the ERG family were up-regulated in both sets of data. However, in general, we found many fewer genes significantly up-or down-regulated under our milder conditions of treatment.
Placing the GFP gene under regulation of the SAP2 promoter resulted in enhanced fluorescence when cells were exposed to fluconazole under Sap-inducing conditions (Figure 3) . These results further confirm the role of SAP2 expression as the mechanism underlying increased Sap secretion in response to antifungal agents, and that assay of GFP fluorescence under a SAP promoter is a reasonable surrogate marker for levels of SAP expression.
We have established beyond doubt that several antifungal agents can influence the expression of at least one C. albicans virulence factor in vitro and are now investigating effects of antifungals on other virulence factors. Up-regulation of Sap2 secretion may represent a defence mechanism of the fungi in response to exposure to antifungal agents at subinhibitory concentrations. It is possibly a collateral effect resulting from alteration of expression of other genes as a physiological response to antifungal agents. We are currently investigating the mechanism underlying the Sap response to antifungal exposure.
